Cover Image
市場調查報告書

法布瑞氏症:開發中產品分析

Fabry Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200448
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
法布瑞氏症:開發中產品分析 Fabry Disease - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 67 Pages
簡介

法布瑞氏症是遺傳性疾病,是由於體內血管壁稱作globotriaosylceramide(GL-3)的特定脂肪物質異常堆積而發病。症候有疼痛,腹瀉,噁心,腎臟障礙,耳鳴,心律不整,心臟瓣膜症等,治療方法為使用酵素補充療法等。

本報告提供法布瑞氏症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

法布瑞氏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

法布瑞氏症:企業開發中的治療藥

法布瑞氏症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

法布瑞氏症:企業開發中的產品

法布瑞氏症的治療藥的開發企業

  • Actelion Ltd
  • Alexion Pharmaceuticals Inc
  • Amicus Therapeutics, Inc.
  • Genzyme Corporation
  • Greenovation Biotech GmbH
  • ISU ABXIS Co.,Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

法布瑞氏症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

法布瑞氏症:暫停中的計劃

法布瑞氏症:開發中止的產品

法布瑞氏症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9078IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.

Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fabry Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fabry Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 2 and 4 respectively.

Fabry Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fabry Disease - Overview
  • Fabry Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
  • Products under Development by Companies
  • Fabry Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fabry Disease - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Amicus Therapeutics Inc
    • Genzyme Corp
    • greenovation Biotech GmbH
    • JCR Pharmaceuticals Co Ltd
    • Neuraltus Pharmaceuticals Inc
    • Pharming Group NV
    • Protalix BioTherapeutics Inc
    • Sangamo Therapeutics Inc
    • Shire Plc
  • Fabry Disease - Drug Profiles
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVR-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enzyme Replacement Therapy + migalastat hydrochloride Biobetter - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibiglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lucerastat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • migalastat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOSS-AGAL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegunigalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGN-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBLSD-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fabry Disease - Dormant Projects
  • Fabry Disease - Discontinued Products
  • Fabry Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2017: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Italy
      • Feb 27, 2017: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in the United Kingdom
      • Feb 16, 2017: Gene therapy used to treat Fabry disease - a world first
      • Feb 14, 2017: Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium 2017
      • Jan 04, 2017: National Institute for Health and Care Excellence Issues Final Positive Recommendation for Galafold (migalastat) for Fabry Disease in England
      • Nov 28, 2016: Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease
      • Nov 11, 2016: Journal of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study of Migalastat for Patients with Fabry Disease
      • Oct 25, 2016: Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease
      • Sep 07, 2016: Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism
      • Aug 31, 2016: Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism Annual Symposium
      • Aug 10, 2016: New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
      • Aug 10, 2016: Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
      • Aug 03, 2016: Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
      • Aug 02, 2016: Almac Group's Integrated Development to Commercialisation Services Support Amicus Therapeutics' First Commercial Orphan Drug Product
      • Jun 06, 2016: Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fabry Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Fabry Disease - Pipeline by Actelion Ltd, H1 2017
  • Fabry Disease - Pipeline by Amicus Therapeutics Inc, H1 2017
  • Fabry Disease - Pipeline by Genzyme Corp, H1 2017
  • Fabry Disease - Pipeline by greenovation Biotech GmbH, H1 2017
  • Fabry Disease - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
  • Fabry Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
  • Fabry Disease - Pipeline by Pharming Group NV, H1 2017
  • Fabry Disease - Pipeline by Protalix BioTherapeutics Inc, H1 2017
  • Fabry Disease - Pipeline by Sangamo Therapeutics Inc, H1 2017
  • Fabry Disease - Pipeline by Shire Plc, H1 2017
  • Fabry Disease - Dormant Projects, H1 2017
  • Fabry Disease - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Fabry Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top